We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on the week, according to data from etfdb.com. Only non-leveraged funds were considered.
A panel of head and neck cancer experts discussed the nuances of managing relapsed or refractory DTC with lenvatinib or sorafenib, as well as sequencing considerations with targeted therapies in the second-line setting and beyond for patients with relapsed or refractory disease.
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) insider Percy H. Carter sold 2,307 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $52.06, for a total value of $120,102.42. Following the sale, the insider now owns 38,117 shares in the company, valued at […]
SVB Securities cut shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a market perform rating to an underperform rating in a research report released on Monday, The Fly reports. They currently have $43.00 price objective on the biotechnology company’s stock, down from their prior price objective of $48.00. BPMC has been the subject of […]